November 19, 2019
Why is it critical for researchers to take the time to validate their antibodies and protocols used in specific applications? Associate Editor Crystal Ripplinger (University of California Davis) interviews lead author Rebekah Gundry (University of Nebraska Medical Center) and Deputy Editor Merry Lindsey (University of Nebraska Medical Center) about this unique Perspective by Matthew Waas and Rebekah Gundry that proposes an approach for antibody validation for flow cytometry assessment of stem cell-derived cardiomyocytes used in cardiovascular physiology and translational research. We address the rigor and reproducibility hurdles researchers face when standardizing immunophenotyping protocols, as well as the challenges of including sufficient experimental details in manuscripts when faced with publisher-mandated manuscript word counts. Waas and Gundry call for moving away from the term “validation” and instead adopting “fit-for-purpose.” How does this fit with the concept of “trust but verify” and new NIH antibody authentication documents required for grant submissions? Listen now.
Matthew Waas and Rebekah L. Gundry A call to adopt a 'fit-for-purpose' approach to antibody validation for flow cytometry analyses of stem cell models and beyond Am J Physiol Heart Circ Physiol, published October 23, 2019. DOI: doi.org/10.1152/ajpheart.00347.2019
November 18, 2019
Can neuromodulation be used to change the sensory transduction of the ischemic ventricle? To answer this question, Editor-in-Chief Dr. Irving H. Zucker (University of Nebraska Medical Center) interviewed lead author Jeffrey Ardell ( University of California Los Angeles) and content expert Marc Kaufman (Pennsylvania State University) about the new work by Salavatian et al. Ardell and co-authors found that preemptive spinal cord stimulation can reduce the afferent signal coming from the ischemic ventricle. Was this a result of a change in substrate utilization in the heart or was this “silent ischemia”? Does this spinal cord stimulation work by Ardell and collaborators have the potential to translate to reducing pain for patients with angina? Don’t miss the extra “off the record” commentary at the end to find out.
Siamak Salavatian, Sarah M. Ardell, Mathew Hammer, David Gibbons, J. Andrew Armour, Jeffrey L. Ardell Thoracic spinal cord neuromodulation obtunds dorsal root ganglion afferent neuronal transduction of the ischemic ventricle Am J Physiol Heart Circ Physiol, published November 4, 2019. DOI: doi.org/10.1152/ajpheart.00257.2019
November 7, 2019
It’s well known that myocardial cell death leads to cardiac remodeling and heart failure. It is, however, less well known exactly which mechanisms lead to myocyte cell death in the heart. In our latest podcast, Associate Editor Junichi Sadoshima (Rutgers New Jersey Medical School) interviews lead authors Paras Mishra (University of Nebraska Medical Center), Joseph Hill (University of Texas Southwestern Medical Center), Peter Kang (Beth Israel Deaconess Medical Center), James Downey (University of South Alabama) and Takashi Matsui (University of Hawaii at Manoa) about their recent comprehensive Guidelines in Cardiovascular Research article on evaluating myocardial cell death. Listen as our experts—all of whom are global thought-leaders in their individual fields—delve into the 6 main mechanisms of cell death in the heart: apoptosis, ferroptosis, autophagic cell death, necroptosis, MPT-mediated necrosis, pyroptosis, autosis.
Paras K. Mishra, Adriana Adameová, Joseph A. Hill, Christopher P. Baines, Peter M. Kang, James Downey, Jagat Narula, Masafumi Takahashi, Antonio Abbate, Hande C. Piristine, Sumit Kar, Shi Su, Jason K. Higa, Nicholas K. Kawasaki, Takashi Matsui Guidelines for evaluating myocardial cell death Am J Physiol Heart Circ Physiol, published October 23, 2019. DOI: doi.org/10.1152/ajpheart.00259.2019